Virpax Pharmaceuticals (VRPX) News Today → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free VRPX Stock Alerts $3.10 +0.18 (+6.16%) (As of 02:29 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023investorplace.com - April 24 at 3:06 PMVirpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutionsmsn.com - April 2 at 11:02 AMVirpax Pharmaceuticals Reports 2023 Year-End Resultsbusinesswire.com - March 26 at 7:30 AMmarketbeat.com - March 1 at 9:37 AMmarketbeat.com - March 1 at 6:15 AMVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Pricefinance.yahoo.com - February 27 at 10:21 AMVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Pricebusinesswire.com - February 27 at 7:31 AMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.businesswire.com - February 27 at 7:30 AMVirpax Pharmaceuticals Reports Promising Results in Probudur Pilot Studymsn.com - February 12 at 7:33 AMAnalysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)markets.businessinsider.com - February 9 at 7:40 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)markets.businessinsider.com - February 7 at 3:59 PMVirpax Pharmaceuticals Inc (VRPX)investing.com - January 23 at 1:47 PMVirpax Pharmaceuticals shareholders okay reverse stock splitmsn.com - December 29 at 7:54 PMTitan Pharmaceuticals to conduct 1-for-20 reverse stock splitmsn.com - December 28 at 6:06 PMVRPX Virpax Pharmaceuticals, Inc.seekingalpha.com - November 22 at 3:08 PMPromising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax Pharmaceuticalsmarkets.businessinsider.com - November 18 at 12:51 AMVirpax Pharmaceuticals gets non-compliance notice from Nasdaqmsn.com - November 17 at 9:20 AMVirpax Pharmaceuticals CEO and Chairman resigns on ongoing litigationmsn.com - November 17 at 9:20 AMVirpax Pharmaceuticals Announces Leadership Transitionfinance.yahoo.com - November 17 at 9:20 AMVirpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filingfinance.yahoo.com - November 17 at 9:20 AMVirpax Pharmaceuticals GAAP EPS of -$0.51msn.com - November 15 at 7:29 PMVirpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Reviewfinance.yahoo.com - October 31 at 10:01 AMAnalysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)markets.businessinsider.com - September 28 at 4:00 PMVirpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studiesfinance.yahoo.com - September 27 at 1:53 PMVirpax Pharmaceuticals to Present at the LD Micro Main Event XVIfinance.yahoo.com - September 26 at 2:19 PMAltasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Virusesbusinesswire.com - September 21 at 11:01 AMVirpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticalsfinance.yahoo.com - September 18 at 12:53 PMVirpax slips as court rules in favor of Scilex and Sorrentomsn.com - September 5 at 5:55 PMVirpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 28 at 12:06 PMMaxim Group Remains a Buy on Virpax Pharmaceuticals (VRPX)markets.businessinsider.com - August 15 at 6:09 PMVirpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Methodfinance.yahoo.com - August 10 at 9:25 AMVirpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023finance.yahoo.com - July 24 at 10:36 AMVirpax Pharmaceuticals Files Provisional Patent Application for Intranasal Deliveryfinance.yahoo.com - July 13 at 12:14 PMVirpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Councilfinance.yahoo.com - June 21 at 9:13 AMVirpax Pharmaceuticals Announces CFO Transitionfinance.yahoo.com - June 20 at 6:32 PMVirpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETfinance.yahoo.com - June 13 at 6:17 PMVirpax Pharmaceuticals GAAP EPS of -$0.13 beats by $0.17msn.com - May 12 at 7:40 PMVirpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminarfinance.yahoo.com - May 10 at 8:38 AMVirpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023finance.yahoo.com - May 4 at 10:53 AMVirpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™finance.yahoo.com - April 27 at 9:21 AMNanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canadabenzinga.com - April 13 at 7:11 AMMaxim Group Keeps Their Buy Rating on Virpax Pharmaceuticals (VRPX)markets.businessinsider.com - April 6 at 5:39 PMVirpax Reports on Progress of Envelta™finance.yahoo.com - April 5 at 10:50 AMVirpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directorsfinance.yahoo.com - March 28 at 10:28 AMVirpax Pharmaceuticals Reports 2022 Year-End Resultsfinance.yahoo.com - March 22 at 2:02 PMVirpax Pharmaceuticals 2022 R&D Expenses Grow 122% To $10.8M, Here Are The Detailsbenzinga.com - March 22 at 10:47 AMMaxim Group Reaffirms Their Buy Rating on Virpax Pharmaceuticals (VRPX)markets.businessinsider.com - February 14 at 11:58 AMVirpax Completes FDA Required Preclinical Toxicology Studies For Its Licensed Molecular Envelope Technologymsn.com - February 13 at 12:49 PMVirpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)finance.yahoo.com - February 13 at 12:49 PMVirpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in Chinafinance.yahoo.com - January 31 at 1:29 PM Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. VRPX Media Mentions By Week VRPX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRPX News Sentiment▼1.220.33▲Average Medical News Sentiment VRPX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRPX Articles This Week▼20▲VRPX Articles Average Week Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CING News BPTS News EVOK News KTRA News MBIO News THAR News ZVSA News PCSA News GNPX News NEXI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRPX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
